FY2025 Earnings Forecast for IQVIA Issued By Leerink Partnrs

Key Points

• Leerink Partners has downgraded their FY2025 earnings per share (EPS) estimate for IQVIA to $10.94, slightly below the previous estimate of $10.97, while the consensus estimate stands at $10.84.
• IQVIA reported better-than-expected quarterly earnings of $2.81 EPS, exceeding analyst estimates, and achieved a revenue of $4.02 billion, which is a year-over-year increase of 5.3%.
• Multiple analysts have boosted their target prices for IQVIA, with Mizuho raising it from $190 to $225 and Barclays from $185 to $200, reflecting a generally positive outlook for the stock.

IQVIA Holdings Inc. (NYSE:IQV - Free Report) - Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for IQVIA in a report issued on Wednesday, October 8th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will post earnings of $10.94 per share for the year, down from their previous estimate of $10.97. The consensus estimate for IQVIA's current full-year earnings is $10.84 per share. Leerink Partnrs also issued estimates for IQVIA's FY2026 earnings at $12.02 EPS, FY2027 earnings at $13.39 EPS and FY2028 earnings at $14.83 EPS.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period in the prior year, the company posted $2.64 EPS. IQVIA's quarterly revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS.

Several other equities research analysts also recently weighed in on the stock. Robert W. Baird boosted their target price on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Weiss Ratings reissued a "hold (c)" rating on shares of IQVIA in a report on Wednesday. Barclays lifted their target price on IQVIA from $185.00 to $200.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 2nd. Mizuho boosted their price target on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Finally, Cowen restated a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $236.45.

IQVIA Trading Up 1.3%

IQV opened at $203.16 on Friday. IQVIA has a 12-month low of $134.65 and a 12-month high of $237.34. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The stock has a market capitalization of $34.54 billion, a PE ratio of 29.40, a P/E/G ratio of 2.20 and a beta of 1.32. The firm's fifty day moving average price is $188.70 and its 200 day moving average price is $168.15.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

Institutional Trading of IQVIA

Hedge funds have recently added to or reduced their stakes in the business. Canada Pension Plan Investment Board increased its holdings in shares of IQVIA by 7.3% during the first quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company's stock valued at $810,069,000 after purchasing an additional 312,807 shares during the period. Alliancebernstein L.P. grew its position in IQVIA by 0.6% in the 2nd quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company's stock valued at $560,379,000 after buying an additional 19,573 shares in the last quarter. Artisan Partners Limited Partnership acquired a new position in IQVIA during the 2nd quarter valued at about $515,772,000. JPMorgan Chase & Co. raised its position in shares of IQVIA by 22.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company's stock worth $492,659,000 after buying an additional 581,157 shares in the last quarter. Finally, Nordea Investment Management AB lifted its stake in shares of IQVIA by 41.7% in the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company's stock worth $326,274,000 after acquiring an additional 606,391 shares during the period. Institutional investors own 89.62% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.